Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON31682
NL-OMON31682
Not Yet Recruiting
N/A

Genetic and Radiological Screening of First Degree Family Members of Patients with Familial Liver Adenomatosis - Familial Liver Adenomatosis

Academisch Medisch Centrum0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbenign liver tumorliveradenomatosis100198061001965410019813

Overview

Phase
N/A
Intervention
Not specified
Conditions
benign liver tumor
Sponsor
Academisch Medisch Centrum
Enrollment
40
Status
Not Yet Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients diagnosed with liver adenomatosis by histology or imaging studies
  • •2\. First line family members of 1\.
  • •2\. Minimal age 18 years old
  • •3\. Informed consent must be obtained

Exclusion Criteria

  • •1\. Patients under 18 years of age
  • •2\. Patients who are pregnant
  • •3\. Patients who are claustrofobic (MRI)
  • •4\. Patients who have magnetic or radiofrequency sensitive implants (MRI)
  • •5\. Patients with extreme obesity (MRI\+US)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
N/A
Genetic Newborn Screening for Rare Diseases within the Screen4Care Projectgenetic newborn screening
DRKS00033501niversitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen20,000
Recruiting
N/A
Genetic screening of an at-risk population for Hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjects
DRKS00016158Centogene AG Rostock5,000
Completed
N/A
Evaluation of Chromosomal Genetic Abnormalities in Cells in Urine Using UroVysioBladder cancer
JPRN-UMIN000015194roVysion Domestic Japanese Clinical Performance Trial Steering Committee450
Active, Not Recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)
EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, Not Recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)
EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100